Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

156 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ALK fusion NSCLC oncogenes promote survival and inhibit NK cell responses via SERPINB4 expression.
Chuang TP, Lai WY, Gabre JL, Lind DE, Umapathy G, Bokhari AA, Bergman B, Kristenson L, Thorén FB, Le A, Doebele RC, Van den Eynden J, Palmer RH, Hallberg B. Chuang TP, et al. Among authors: doebele rc. Proc Natl Acad Sci U S A. 2023 Feb 21;120(8):e2216479120. doi: 10.1073/pnas.2216479120. Epub 2023 Feb 15. Proc Natl Acad Sci U S A. 2023. PMID: 36791109 Free PMC article.
A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV non-small-cell lung cancer.
Camidge DR, Berge EM, Doebele RC, Ballas MS, Jahan T, Haigentz M Jr, Hoffman D, Spicer J, West H, Lee P, Yang L, Joshi A, Gao L, Yurasov S, Mita A. Camidge DR, et al. Among authors: doebele rc. J Thorac Oncol. 2014 Oct;9(10):1532-9. doi: 10.1097/JTO.0000000000000273. J Thorac Oncol. 2014. PMID: 25170639 Free PMC article. Clinical Trial.
Author Correction: GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers.
Bianco G, Coto-Llerena M, Gallon J, Kancherla V, Taha-Mehlitz S, Marinucci M, Konantz M, Srivatsa S, Montazeri H, Panebianco F, Tirunagaru VG, De Menna M, Paradiso V, Ercan C, Dahmani A, Montaudon E, Beerenwinkel N, Kruithof-de Julio M, Terracciano LM, Lengerke C, Jeselsohn RM, Doebele RC, Bidard FC, Marangoni E, Ng CKY, Piscuoglio S. Bianco G, et al. Among authors: doebele rc. Commun Biol. 2022 Jul 4;5(1):658. doi: 10.1038/s42003-022-03612-5. Commun Biol. 2022. PMID: 35787660 Free PMC article. No abstract available.
A novel interplay between Epac/Rap1 and mitogen-activated protein kinase kinase 5/extracellular signal-regulated kinase 5 (MEK5/ERK5) regulates thrombospondin to control angiogenesis.
Doebele RC, Schulze-Hoepfner FT, Hong J, Chlenski A, Zeitlin BD, Goel K, Gomes S, Liu Y, Abe MK, Nor JE, Lingen MW, Rosner MR. Doebele RC, et al. Blood. 2009 Nov 12;114(20):4592-600. doi: 10.1182/blood-2009-04-217042. Epub 2009 Aug 26. Blood. 2009. PMID: 19710505 Free PMC article.
Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma.
Camidge DR, Blais N, Jonker DJ, Soulières D, Doebele RC, Ruiz-Garcia A, Thall A, Zhang K, Laurie SA, Chao RC, Chow LQ. Camidge DR, et al. Among authors: doebele rc. Cancer Chemother Pharmacol. 2013 Feb;71(2):307-19. doi: 10.1007/s00280-012-2008-6. Epub 2012 Oct 30. Cancer Chemother Pharmacol. 2013. PMID: 23108697 Clinical Trial.
Accessory molecules for MHC class II peptide loading.
Busch R, Doebele RC, Patil NS, Pashine A, Mellins ED. Busch R, et al. Among authors: doebele rc. Curr Opin Immunol. 2000 Feb;12(1):99-106. doi: 10.1016/s0952-7915(99)00057-6. Curr Opin Immunol. 2000. PMID: 10679402 Review.
156 results